Shire reports top-line results on OPUS-2, a Phase 3 study investigating the use of Lifitegrast in adults with dry eye disease
Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, has announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution. OPUS-2 compared lifitegrast to placebo administered twice daily for 84 days (12 weeks) in dry eye patients with history of active artificial tear use within 30 days prior to screening.